Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
Allogene Therapeutics, Inc. (ALLO) Debt to Equity Ratio data is not available for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$4.64M |
|
$-42.68M |
|
-- |
|
$4.64M |
|
$51.56M |
|
$-46.92M |
|
$4.24M |
|
$-42.68M |
|
$-42.68M |
|
$-42.68M |
|
$-42.68M |
|
$-42.68M |
|
$-42.68M |
|
$-46.92M |
|
$-45.59M |
|
328.93M |
|
328.93M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$340.00M |
|
$67.38M |
|
$210.09M |
|
$550.09M |
|
$31.73M |
|
-- |
|
$82.19M |
|
$113.92M |
|
$436.18M |
|
$436.18M |
|
$436.18M |
|
345.35M |
|
| Cash Flow Statement Financials | |
$-44.91M |
|
$-177.15M |
|
$208.99M |
|
$61.98M |
|
$48.92M |
|
$-13.06M |
|
$20.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.72 |
|
-- |
|
-- |
|
-- |
|
|
Debt to Equity Ratio |
-- |
100.00% |
|
-1011.21% |
|
-1011.21% |
|
-- |
|
-919.76% |
|
-919.76% |
|
$-45.07M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-9.78% |
|
-9.78% |
|
-7.76% |
|
-9.78% |
|
$1.26 |
|
$-0.14 |
|
$-0.14 |
|